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ABSTRACT: This session focused on three topics related to clin-
ical development of novel anticancer therapies: (1) moving clini-
cal testing of new agents in early-stage, (2) strategies for clinical
evaluation of combinations between novel/molecularly targeted
agents, and (3) clinical development paradigm for vaccine related
biological therapeutics.
Monotherapy with molecularly targeted agents has up to now
only offered little clinical benefit in most solid tumours where the
molecular pathology has not been linked to a single genetic defect
or target. While the importance of combining targeted agents is
well recognized, clinical development of novel combination stud-
ies can be challenging, and requires careful considerations of the
regulatory, intellectual property as well as scientific issues.
Traditional design of clinical trials must be adapted to test the
clinical utility of new targeted agents in different settings and to
allow for translational research.
Cancer vaccines present unique developmental challenges.
Some potential solutions exist, but they are not widely known
nor is there any consensus about their use. A Cancer Vaccine Con-
sortium (CVC) was established with the goal to use collective
knowledge in the field to synthesize a flexible and applicable par-
adigm, reach a consensus on practical recommendations to
improve cancer vaccine development, and offer an accepted,
practical approach to cancer vaccine development.
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As anti-cancer drug discovery has shifted to a rational, molec-
ularly targeted approach, traditional clinical trial design must be
adapted to test the clinical utility of these new agents.1 Tradi-
tional cytotoxic drugs, which evolved from the concept that can-
cer could be cured by eradicating all cancer cells in the body, have
diverse mechanisms of action, but mostly target DNA. Their phar-
macological effects are non-selective and irreversible, affecting
all cells undergoing replication, normal and neoplastic. Dosing
is usually in cyclical pulses administered at the maximum toler-
ated dose (MTD), which results in substantial toxicity in many
patients. Phase I studies aim to establish the MTD, and phase II
studies assess response based on tumour shrinkage, usually mea-
sured by imaging techniques.
In contrast, target-based therapies are selected on the basis of
their mechanism of action and usually target a specific protein
that is involved in malignant transformation. The interaction
with their target (receptor or ligand) can be described by classical
drug–receptor theory. Pharmacological effects are generally
reversible. Dosing can be continuous at a tolerable dose. Phase I
studies use biological and pharmacokinetic endpoints to estimate
the optimal dose for inhibition of the target. Response assess-
ments in phase II is based on prevention of further tumour
growth, rather than tumour shrinkage. For many molecularly tar-
geted agents, phase I is relatively uninformative, the heteroge-
neous patient population often has late-stage disease with
limited organ reserves and co-morbidities. Toxicities are uncom-
mon, and the maximum therapeutic effect is usually achieved
well below MTD. The goal is to estimate the optimal biological
dose (OBD), gauge the interaction between the anticancer agent
and its target, and to rule out serious dose-related toxicities. For
phase II development, the goal is to assess the probability that
the product will have a positive benefit-risk ratio in phase III. This
assessment is made by focusing on important pathways and ‘fol-
lowing the biology’. Assessments often include multiple tumour
types and involve monitoring of biomarkers and surrogates of
patient benefit. Also in phase II, the frequency of safety events
is estimated.
Phase III development of targeted agents is similar to that for
cytotoxic agents; that is, it involves measuring clinical benefit
against a known standard of care (active comparator) in random-
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